Novartis' MenB vaccine Bexsero set for blockbuster status after new data
This article was originally published in Scrip
Executive Summary
Data presented this week indicate that Novartis's novel meningococcal B vaccine Bexsero has the potential to fill the one unmet need that remains in the meningococcal space – a safe vaccine with broad efficacy against serogroup B infections. Critics have been concerned that Bexsero causes increased rates of fever, but these fears were dampened by additional results presented at the World Vaccines Congress in Washington DC, paving the way for Bexsero to become Novartis's next big blockbuster.